Comparison

Anti-Human CD20 (Rituximab) [Clone 10F381] – DyLight® 488 - 100 µg

Item no. LEIN-LT911-100ug
Manufacturer Leinco Technologies
Amount 100 ug
Category
Type Antibody Monoclonal
Applications FC
Clone 10F381
Specific against Human (Homo sapiens), Monkey (Cynomolgus, Simian), Rhesus macaque
Host Human
NCBI 931
ECLASS 10.1 42030590
ECLASS 11.0 42030590
UNSPSC 12352203
Shipping Condition Cool pack
Available
Manufacturer - Applications
Quality Tested by Leinco FC The suggested concentration for Rituximab biosimilar antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application.
Manufacturer - Category
Recombinant Antibodies>Biosimilar Recombinant Antibodies
Manufacturer - Targets
CD20
Country of Origin
USA
Shipping Temperature
Next Day 2 - 8°C
Storage Conditions
This DyLight® 488 conjugate is stable when stored at 2-8°C. Do not freeze.
Product Description
CD20 is a 33-37 kD transmembrane-spanning phosphoprotein found on the surface of developing B-cells and various B-cell malignancies. CD20 is a popular target for mAb therapy because depleting developing B-cells generally does not cause permanent side effects (due to the fact that mature plasma cells and B-cell progenitors do not express CD20 and that there is limited expression of CD20 among other cell lineages). Rituximab is a chimeric monoclonal antibody that binds to CD20. The precise function of CD20 is still unknown. However, it is suspected to play a role in Ca2+ influx across plasma membranes, maintaining intracellular Ca2+ concentration, and allowing the activation of B cells. Rituximab is used to treat some autoimmune diseases and types of cancer such as non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis among others. The Fc portion of Rituximab mediates antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Rituximab increases MHC II and adhesion molecules LFA-1 and LFA-3 (lymphocyte function-associated antigen) and also induces apoptosis of CD20+ cells. This ultimately results in the elimination of B cells (including the cancerous ones) from the body, and thus allows a new population of healthy B cells to develop from lymphoid stem cells. Anti-Human CD20 (Rituximab) utilizes the same variable regions from the therapeutic antibody Rituximab making it ideal for research projects.
Background
CD20 is a 33-37 kD transmembrane-spanning phosphoprotein found on the surface of developing B-cells and various B-cell malignancies. CD20 is a popular target for mAb therapy because depleting developing B-cells generally does not cause permanent side effects (due to the fact that mature plasma cells and B-cell progenitors do not express CD20 and that there is limited expression of CD20 among other cell lineages). Rituximab is a chimeric monoclonal antibody that binds to CD20. The precise function of CD20 is still unknown. However, it is suspected to play a role in Ca2+ influx across plasma membranes, maintaining intracellular Ca2+ concentration, and allowing the activation of B cells. Rituximab is used to treat some autoimmune diseases and types of cancer such as non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis among others. The Fc portion of Rituximab mediates antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Rituximab increases MHC II and adhesion molecules LFA-1 and LFA-3 (lymphocyte function-associated antigen) and also induces apoptosis of CD20+ cells. This ultimately results in the elimination of B cells (including the cancerous ones) from the body, and thus allows a new population of healthy B cells to develop from lymphoid stem cells. Anti-Human CD20 (Rituximab) utilizes the same variable regions from the therapeutic antibody Rituximab making it ideal for research projects.
PubMed
CD20
Excitation Laser
Blue Laser (493 nm)
Manufacturer - Research Area
Biosimilars, Costimulatory Molecules, Immunology
Manufacturer - Expression host
HEK-293
Manufacturer - Specificity
This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Rituximab. Clone 10F381 recognizes human CD20. This product is for research use only.
FC Effector Activity
Active
RRID
AB_2894036
Concentration
0.2 mg/ml
Formulation
This DyLight® 488 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Antigen Distribution
CD20 is primarily found on the surface of immune system B cells. CD20 is highly expressed in the lymph node, and to a lesser extent, the spleen and appendix.
Immunogen
Human lymphoblastoid cell line SB.
Regulatory Status
Research Use Only (RUO). Non-Therapeutic.
Additional Information
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.
Keywords
B1; S7; Bp35; CD20; CVID5; MS4A2; LEU-16; MS4A1; membrane spanning 4-domains A1; Rituximab; biosimilar; r-Biosimilars; Chronic lymphocytic leukemia; Rituximab

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 100 ug
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close